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Merkel Cell Polyomavirus Small T Antigen Is
Oncogenic in Transgenic Mice
Monique E. Verhaegen1,8, Doris Mangelberger1,8, Paul W. Harms1,2, Tracy D. Vozheiko1, Jack W. Weick1,
Dawn M. Wilbert1, Thomas L. Saunders3, Alexandre N. Ermilov1, Christopher K. Bichakjian1,
Timothy M. Johnson1,4,5, Michael J. Imperiale6 and Andrzej A. Dlugosz1,7
Merkel cell carcinoma (MCC) is a rare and deadly neuroendocrine skin tumor frequently associated with clonal
integration of a polyomavirus, Merkel cell polyomavirus (MCPyV), and MCC tumor cells express putative
polyomavirus oncoprotein small T antigen (sTAg) and truncated large T antigen. Here, we show robust
transforming activity of sTAg in vivo in a panel of transgenic mouse models. Epithelia of preterm sTAg-expressing
embryos exhibited hyperplasia, impaired differentiation, increased proliferation, and apoptosis, and activation of
a DNA damage response. Epithelial transformation did not require sTAg interaction with the protein phosphatase
2A protein complex, a tumor suppressor in some other polyomavirus transformation models, but was strictly
dependent on a recently described sTAg domain that binds Fbxw7, the substrate-binding component of the Skp1/
Cullin1/F-box protein ubiquitin ligase complex. Postnatal induction of sTAg using a Cre-inducible transgene also
led to epithelial transformation with development of lesions resembling squamous cell carcinoma in situ and
elevated expression of Fbxw7 target proteins. Our data establish that expression of MCPyV sTAg alone is
sufficient for rapid neoplastic transformation in vivo, implicating sTAg as an oncogenic driver in MCC and
perhaps other human malignancies. Moreover, the loss of transforming activity following mutation of the sTAg
Fbxw7 binding domain identifies this domain as crucial for in vivo transformation.
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INTRODUCTION
Merkel cell carcinoma (MCC) is a rare and deadly neuroendo-
crine malignancy that arises primarily in the skin (Bichakjian
et al., 2007). Although MCC can be cured at early stages, the
5-year relative survival rate of patients with lymph node
involvement is 39%, and a mere 18% for those individuals
with distant metastases (Lemos et al., 2010). MCC tumor cells
share several markers in common with normal Merkel cells,
specialized cells required for transmission of light touch
(Maricich et al., 2009) and that arise from progenitors in the
epidermis (Morrison et al., 2009; Van et al., 2009). However,
the cell of origin of MCC is not known (Tilling and Moll, 2012).
The lack of effective treatments for advanced MCC has
fueled studies into the molecular basis of MCC with the hope
of identifying new targets for therapy. A pivotal report by
Moore and coworkers identified a novel polyomavirus, named
Merkel cell polyomavirus (MCPyV), in 8 of 10 human MCC
samples by digital transcriptome subtraction (Feng et al.,
2008). Subsequent studies confirmed these findings, with
B75% of MCCs harboring MCPyV sequence (reviewed in
Jaeger et al. (2012)). Polyomaviruses are double-stranded
DNA viruses that include murine polyomavirus, simian virus
40, and at least 12 human polyomaviruses, including
MCPyV and several other polyomaviruses identified
specifically in the skin (DeCaprio and Garcea, 2013).
Although several polyomaviruses have been implicated in
human cancer development (Zur Hausen, 2008), compelling
evidence supporting this concept is limited to MCPyV, making
this virus a crucial focus for investigation.
MCPyV DNA in MCCs is integrated clonally (Feng et al.,
2008), strongly suggesting that this virus is present at tumor
initiation and that one or more viral proteins function as
oncogenic drivers. Similar to that of other polyomaviruses, the
MCPyV genome contains an early region with genes encoding
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the putative transforming antigens large T (LTAg) and small T
(sTAg) and a late region with genes encoding the viral capsid
components (DeCaprio and Garcea, 2013). MCPyV-positive
tumor cells express sTAg and LTAg with tumor-specific
C-terminal truncations (truncated LTAg, tLTAg), which disrupt
viral helicase activity but retain the consensus domain for
binding to the retinoblastoma 1 (RB1) tumor suppressor protein
(Shuda et al., 2008). TAgs from other polyomaviruses
contribute to transformation and tumorigenesis by interacting
with key cellular factors: most LTAgs disrupt the function of
RB1 and TP53 tumor suppressors, whereas sTAgs inhibit the
protein phosphatase 2A (PP2A) tumor suppressor complex
(Dalianis and Hirsch, 2013; DeCaprio and Garcea, 2013). In
general, LTAg is the dominant transforming oncogene for most
polyomaviruses, and sTAg either does not transform or does so
with low efficiency but cooperates to mediate the full
transformation potential of LTAg (reviewed in Khalili et al.
(2008)). It was recently reported that MCPyV encodes a third
early protein called ALTO whose role in transformation, if any,
is not yet known (Carter et al., 2013).
MCPyV sequences have been detected in various tumor
types other than MCC, but the significance of these findings is
unclear in light of the widespread prevalence of this virus in
the general population, the generally low virus copy number
in non-MCC tumors, and detection of MCPyV sequences in
normal tissues as well as cancer tissues. Interestingly, a small
number of MCPyV-positive cases of chronic lymphocytic
leukemia and non–small-cell lung cancer harbor tumor-
specific LTAg mutations and express LTAg protein (Pantulu
et al., 2010; Hashida et al., 2013). In addition, viral integration
was demonstrated in non–small-cell lung cancer (Hashida
et al., 2013), in keeping with a functional role for MCPyV in
the development of tumors other than MCC.
Genetic knockdown of tLTAg and sTAg, or either tLTAg or
sTAg alone, leads to reduced proliferation of MCC cell lines
and/or tumor xenografts, arguing that TAg expression is
required for maintenance of cultured MCC tumor cells
(Houben et al., 2010; Shuda et al., 2014). In other studies,
however, knockdown of either tLTAg (Houben et al., 2012) or
sTAg (Angermeyer et al., 2013) had no effect on tumor cell
proliferation or viability in vitro, raising the possibility that in
some cases, MCPyV may lead to tumor development through
a hit-and-run mechanism (reviewed in Niller et al. (2011)). In
contrast to TAgs from other polyomaviruses, in vitro studies
revealed that MCPyV sTAg, and not LTAg, is capable of
driving a transformed phenotype in rodent fibroblasts (Shuda
et al., 2011; Kwun et al., 2013). This is not dependent on sTAg
interaction with PP2A (Shuda et al., 2011) but does require a
domain that binds Fbxw7 and leads to accumulation of several
cellular oncoproteins and LTAg, designated the LT-
stabilization domain (LSD; Kwun et al., 2013).
Cell culture studies (Shuda et al., 2011; Kwun et al., 2013)
have set the stage for in vivo analysis of MCPyV TAg
transforming potential, which we have now examined using
a panel of transgenic mice carrying wild-type or mutant sTAgs.
We show that expression of sTAg in preterm embryos is
sufficient for transformation of several epithelia including the
skin. The phenotypes are independent of PP2A binding but
strictly dependent on the recently described sTAg LSD. In
adult mice, sTAg drives rapid epidermal hyperplasia and
development of skin lesions resembling squamous cell
carcinoma (SCC) in situ. Our findings identify sTAg as a
powerful oncogenic driver in vivo, support the concept that
MCPyV may have a role in the development of tumors other
than MCC, and establish a strict requirement for the sTAg LSD
for epithelial transformation in mice.
RESULTS
Epithelial transformation in transgenic mouse embryos
expressing MCPyV sTAg
We used a transgenic cassette with 5.3 kb bovine keratin 5
(K5) promoter (Ramirez et al., 1994) to target expression of
sTAg to the epidermis and several other epithelia. We con-
structed the K5-sTAg transgene with an internal ribosomal
entry site (IRES) and tdTomato complementary DNA (cDNA)
downstream of sTAg, enabling us to use immunostaining for
red fluorescent protein (RFP; tdTomato) as an indicator of
transgene expression (Figure 1a, Supplementary Table S1
online). As we could not predict the biological response of
K5-targeted cells to sTAg expression, we analyzed preterm
transgenic embryos to circumvent a potentially severe pheno-
type incompatible with postnatal survival. Histology of K5-
sTAg embryos revealed striking alterations in several epithelia
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Figure 1. Epithelial transformation in preterm mouse embryo expressing
MCPyV sTAg. (a) Transgenic cassette including bovine keratin 5 (K5) promoter,
wild-type Merkel cell polyomavirus (MCPyV) small T antigen (sTAg), and
internal ribosomal entry site (IRES)-tdTomato (RFP), designated K5-sTAg.
(b) Histology of indicated epithelia from preterm control and K5-sTAg embryos.
Rectangles indicate regions shown at higher magnification. Note: increased
thickness of epithelia in K5-sTAg mice and loss or reduction of differentiated
granular (white asterisk) and cornified (black asterisk) cell layers seen in
controls. White arrowheads indicate pyknotic nuclei with condensed
chromatin suggestive of apoptosis in K5-sTAg epithelia; black arrowheads
identify suprabasal mitotic figures, which are normally restricted to basal or
immediate suprabasal cell layers. Scale bars¼25mm.
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where the K5 promoter was active, including the skin, tongue,
palate, tooth primordia, and salivary glands (Figure 1b,
Supplementary Table S1 online). The most severe changes
were detected in acral skin and oral cavity and typically
included the replacement of differentiated epithelial cell layers
by an expanded and disorganized epithelium (Figure 1b).
Mitotic cells, largely restricted to the basal and first suprabasal
layer in control epithelia, were detected in mid and upper cell
layers in K5-sTAg mice, and condensed or fragmented nuclei
suggestive of apoptosis were frequently observed, typically
limited to the uppermost strata of affected epithelia
(Figure 1b). Similar changes were seen in multiple indepen-
dent transgenic founders (Supplementary Table S1 online).
MCPyV sTAg drives alterations in epithelial differentiation,
proliferation, and apoptosis
Immunostaining for RFP showed a strong correlation between
transgene expression and epithelial abnormalities. RFP was
not detected or was only present in a small number of cells in
K5-sTAg mice that lacked any apparent phenotypic changes
(Supplementary Table S1 online). In contrast, in embryos with
dysplastic epithelia, RFP was frequently expressed throughout
multiple cell layers (Figure 2a). Analysis of epithelial lineage
markers revealed an altered program of terminal differentia-
tion. Cells expressing K5, normally limited to the basal and
lower suprabasal cell layers, were detected in suprabasal strata
of the epidermis and tongue in K5-sTAg mice (Figure 2b). In
contrast, the number of cell layers expressing the late-stage
epidermal differentiation marker loricrin was reduced
(Figure 2b). In some areas, the outermost cellular compart-
ment in the epidermis, the stratum corneum, was also reduced
in thickness (Figures 1b and 2a).
There was a marked expansion of cells expressing the
proliferation markers Ki67 and pHH3 in affected epithelia
(Figure 2c), and many cells expressed the apoptosis marker
cleaved caspase 3 (CC3), particularly in the upper strata
(Figure 2d). Expression of gH2AX, an indicator of DNA
damage frequently detected in cancer (Bonner et al., 2008),
was also elevated in epithelia of K5-sTAg mice (Figure 2d). In
mosaic founders (Supplementary Table S1 online), the above
alterations were largely limited to RFP-expressing cells, indi-
cating that these epidermal responses to sTAg are largely cell
autonomous. Collectively, these data establish that expression
of MCPyV sTAg in vivo is sufficient to produce multiple
phenotypic alterations that are associated with epithelial
neoplasia.
In vivo transformation by MCPyV sTAg is not dependent on
interaction with PP2A
To begin testing for a potential mechanism regulating sTAg’s
potent transforming activity in vivo, we first focused on the
PP2A tumor suppressor complex (Mumby, 2007; Westermarck
and Hahn, 2008), which is targeted by sTAgs from other
polyomaviruses to alter mammalian cell function (Rodriguez-
Viciana et al., 2006; Sablina and Hahn, 2008; Andrabi et al.,
2011). We modified the K5-sTAg cassette to yield a mutant
sTAg carrying a leucine to alanine substitution at amino acid
142 (sTAgL142A) (Figure 3a), which disrupts interaction with
both the Aa structural subunit and catalytic C subunit of PP2A
(Shuda et al., 2011). The phenotype of K5-sTAgL142A mice
was similar to that of K5-sTAg mice (Figure 3b, Supplementary
Figure S1A and Table S1 online) and included impaired
differentiation, an expanded proliferative compartment, and
nuclear fragmentation (Figure 3b). Immunostaining revealed
an increased proportion of Ki67-expressing cells, impaired
differentiation, increased apoptosis, and expression of gH2AX
(Supplementary Figure S1A online). These data argue that
binding of sTAg to the PP2A tumor suppressor is not required
for in vivo transformation in epithelia.
In vivo transformation by sTAg is strictly dependent on the LSD
which binds Fbxw7
In contrast to the PP2A binding domain, the sTAg LSD is
essential for transformation in cultured cells. Mutant sTAg with
alanine substitutions at amino acids 91–95, which no longer
co-immunoprecipitates with overexpressed Fbxw7 (Kwun
et al., 2013), prevents accumulation of LTAg and several
cellular targets and fails to transform fibroblasts. To test the
in vivo transforming potential of this LSD mutant, we
generated a K5-sTAg91–95A transgenic construct (Figure 4a)
and produced additional transgenic embryos. Strikingly, his-
tology of the epidermis from K5-sTAg91–95A preterm embryos
was indistinguishable from that of controls (Figure 4b), and
immunostaining to detect a panel of epidermal markers, Ki67,
CC3, and gH2AX, supported this impression (Figure 4c). RFP
expression confirmed robust transgene expression in epider-
mal basal cells where the K5 promoter is active under normal
conditions (Figure 4b). Thus, in striking contrast to the robust
in vivo transforming potential of wild-type or PP2A binding–
deficient sTAg, the sTAg LSD mutant fails to drive epithelial
transformation in preterm embryos.
Postnatal activation of MCPyV sTAg leads to epidermal
transformation and squamous cell carcinoma in situ
To assess the transforming potential of sTAg in adult mice, we
engineered Cre-inducible sTAg transgenic mice, designated
KLEsT, using a modified K5 construct (Allen et al., 2003) that
contains a floxed enhanced GFP/STOP sequence upstream of
the sTAg cDNA (Figure 5a). KLEsT mice express green
fluorescent protein (GFP) in K5-expressing cells, but, in the
presence of Cre, recombination at the loxP sites leads to
deletion of the GFP/STOP sequence and transcription of the
previously dormant sTAg cDNA (Figure 5a). We crossed KLEsT
mice with K5-CreERT2 mice (Indra et al., 1999) carrying a
tamoxifen-inducible Cre to generate K5-CreERT2;KLEsT
(iK5;KLEsT) bitransgenic mice. Treatment of these mice with
tamoxifen to activate sTAg expression led to profound
alterations in the epidermis at several body sites including
tail, ear, snout, and volar skin (Figure 5b and c). Affected
epidermis was markedly hyperplastic, with the most striking
changes in ear epidermis, which was over 10-fold thicker than
in control mice (Po0.001; Figure 5d). Cells with condensed or
fragmented nuclei were common and epidermal maturation
was altered in some areas, with the absence of a granular cell
layer, abrupt keratinization, and regions of prominently
thickened stratum corneum containing retained nuclei
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(parakeratosis; Figure 5b). In some areas, the histological
changes were more advanced and included full-thickness
atypia, reduced eosin staining, pyknotic nuclei, and tissue
disorganization, which collectively recapitulate many features
of human SCC in situ (Bowen’s disease; Figure 5e). We
detected sTAg in iK5;KLEsT mice exhibiting a strong epidermal
phenotype using immunoprecipation followed by immuno-
blotting of skin lysates with the 2t2 mAb (Schwitalla et al.,
2013; Figure 5f), which recognizes MCPyV TAgs (Shuda et al.,
2014).
Immunostaining of the skin from adult sTAg-expressing
mice revealed expansion of Ki67-expressing cells and an
increased number of cells expressing CC3 and gH2AX
(Figure 6a), reflecting changes we detected in preterm K5-
sTAg embryos. Immunostaining for lineage markers again
revealed an expanded population of cells expressing K5 and
the appearance of hyperplasia-associated keratins K6 and K17
(Figure 6b and c). Occasionally, expression of the granular cell
marker loricrin and spinous cell marker K10 was focally
reduced or absent beneath regions of parakeratosis
(Figure 6b). Although K20, K8, and synaptophysin were easily
detected in normal Merkel cells, these markers were not
appreciably induced in hyperplastic regions of the epidermis
from iK5;KLEsT mice (Supplementary Figure S2 online). Post-
natal activation of sTAg in cutaneous epithelia thus mimics
many of the changes seen in transgenic embryos, and in some
areas leads to lesions closely resembling human SCC in situ,
but expression of sTAg alone does not appear to be sufficient
to drive epidermal cells into the Merkel cell lineage.
In vivo transformation by sTAg is associated with accumulation
of Fbxw7 targets
The sTAg LSD is required for fibroblast transformation in vitro
(Kwun et al., 2013) and epithelial transformation in vivo
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Figure 2. MCPyV sTAg alters epithelial differentiation, proliferation, and apoptosis. (a) Hematoxylin and eosin (H&E) and red fluorescent protein (RFP) immuno-
staining of acral skin and tongue showing disorganized, hyperplastic epithelia, and widespread transgene (RFP) expression. (b) Expansion of the basal layer marker
keratin 5 (K5) and impaired expression of the granular cell marker loricrin in sTAg-expressing epithelia. (c) Striking upward expansion of Ki67-expressing
proliferating cells and phospho-histone H3 (pHH3)-expressing mitotic cells in sTAg-expressing epidermis. (d) Immunostaining for the apoptosis marker CC3 and
DNA damage response marker gH2AX in sTAg epidermis. Scale bars¼ 25mm.
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(Figure 4) and is proposed to function at least in part by
stabilizing LTAg and cellular proteins targeted for destruction
by the Skp1/Cullin1/F-box (SCF)/Fbxw7 ubiquitin ligase com-
plex (Kwun et al., 2013). We therefore performed immuno-
blotting to assess whether epidermal transformation in adult
mice was associated with accumulation of Fbxw7 targets.
Expression levels of cyclin E, c-Jun, mTOR, and Mcl-1, all of
which are Fbxw7 substrates targeted for destruction by the
SCF/Fbxw7 complex (Koepp et al., 2001; Nateri et al., 2004;
Mao et al., 2008; Inuzuka et al., 2011), were elevated in skin
lysates of iK5;KLEsT mice relative to controls (Figure 6d).
Increased expression of proliferating cell nuclear antigen and
K17 confirmed a hyperplastic response and loss of GFP
indicated efficient recombination of the KLEsT transgene.
These data are in keeping with the idea that binding of sTAg
to Fbxw7 impairs its ability to target key cellular proteins for
ubiquitin-mediated degradation, leading to their accumulation
and potential contribution to sTAg-driven transformation.
DISCUSSION
The discovery of clonally integrated MCPyV viral sequences in
the majority of human MCCs argues that MCPyV TAgs have a
causal role in tumor development. We now present studies
examining the tumorigenic potential of sTAg when expressed
in vivo in preterm transgenic mouse embryos and adult mice.
sTAg expression can promote neoplastic transformation in
epithelia of late-stage mouse embryos in a PP2A-independent
and sTAg LSD–dependent manner, whereas activation of sTAg
in the skin of adult mice leads to similar transformation-related
changes and also drives the development of lesions resem-
bling SCC in situ. These findings establish sTAg as a potent
oncogene in vivo and suggest that it functions as an oncogenic
driver in MCC and potentially other cancers linked to MCPyV.
The strict requirement for the Fbxw7-binding LSD region in
epithelial transformation of preterm embryos, coupled with
the upregulation of multiple oncogenic Fbxw7 targets in adult
mice expressing sTAg, suggests that sTAg-Fbxw7 binding and
stabilization of key cellular substrates may contribute to sTAg-
driven epithelial transformation in vivo.
Epithelial abnormalities in preterm K5-sTAg embryos exhibit
features in common with many neoplasms, including altered
differentiation, an expanded proliferative compartment,
increased apoptosis, and a robust DNA damage response.
To delineate the potential mechanism by which sTAg drives
these profound alterations in cell and tissue function, we
analyzed the response to sTAg mutants defective in binding to
either the tumor suppressor PP2A (sTAgL142A) or Fbxw7
(sTAg91-95A), the substrate-binding component of the SCF
ubiquitin ligase complex, which has tumor suppressor activity
in a broad range of malignancies (reviewed in Cheng and Li
(2012)). We found that the PP2A binding site of sTAg is not
required for epithelial transformation in preterm embryos, in
keeping with results obtained using cultured fibroblasts (Shuda
et al., 2011; Kwun et al., 2013). In contrast, transforming
activity is lost in mice carrying the sTAg91–95A LSD mutant,
which no longer binds Fbxw7 (Kwun et al., 2013); moreover,
the expression of several Fbwx7 substrates is elevated in the
skin of adult mice expressing wild-type sTAg. These data
suggest that sTAg drives transformation in vivo, at least in part,
via upregulation of cellular proteins targeted for destruction by
the SCF/Fbxw7 complex. However, it is unlikely that the loss
of transforming potential of the sTAg91–95A LSD mutant is
solely due to disruption of normal Fbwx7 function, as Fbwx7
knockdown failed to fully restore fibroblast transformation by
the sTAg91–95A LSD mutant (Kwun et al., 2013). Further
studies will be required to define additional functions that are
disrupted in the sTAg91–95A LSD mutant, which may con-
tribute to, or have a central role in, transformation.
The development of SCC in situ in adult mice expressing
sTAg raises the possibility that MCPyV has a role in the
development of other skin tumors or perhaps extracutaneous
malignancies. In keeping with this possibility, MCPyV
sequences have been detected in a few cases of chronic
lymphocytic leukemia and non–small-cell lung cancer, which
harbor tumor-specific LTAg truncations and express tLTAg
protein (Pantulu et al., 2010; Hashida et al., 2013). Of
potential relevance to our findings in adult mice, one study
documented MCPyV mutations that would yield tumor-
specific LTAg truncation in human SCCs (Dworkin et al.,
2009), although viral integration and copy number were not
examined. Unfortunately, immunoreagents to selectively
detect MCPyV sTAg are not readily available; hence, with
the exception of a single report (Shuda et al., 2011),
immunostaining for TAg protein expression in MCPyV-
positive tumors has been limited to LTAg or tLTAg.
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Figure 3. Epithelial transformation by a protein phosphatase 2A (PP2A)
binding–deficient sTAg mutant. (a) Keratin 5 (K5)-sTAgL142A transgene
construction identical to K5-sTAg in Figure 1a, except for L142A substitution,
which blocks sTAg binding to PP2A. (b) Hematoxylin and eosin and RFP
immunostaining in sections from acral skin, tongue, and palate, showing
features of transformation similar to those in K5-sTAg mice and robust
transgene expression. RFP immunostaining is shown in insets. Scale
bars¼ 50mm.
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Although the striking phenotypes seen in embryos and adult
sTAg-expressing mice establish the transforming potential of
sTAg expressed in epithelial cells, we did not detect lesions
resembling MCC either morphologically or biochemically by
immunostaining for a panel of MCC markers. Expression of
sTAg alone in K5-expressing epidermal cells is thus not
sufficient to drive MCC development in the context of this
type of mouse model. This raises questions about the potential
requirement for tLTAg and/or additional somatic mutations in
MCC pathogenesis. As both sTAg and tLTAg appear to be
coexpressed in most MCPyV-positive MCCs and tLTAg is
required for MCC tumor cell maintenance, it seems likely
that tLTAg has an important role in MCC tumorigenesis.
Tumor-specific LTAg truncations are always downstream of
the domain that binds the tumor suppressor RB1, which may
be a critical cellular target for MCPyV, as it is in human
papillomavirus–associated cancer. In keeping with this con-
cept, MCCs that are MCPyV-negative have either lost or
reduced endogenous RB1 expression (Sihto et al., 2011;
Harms et al., 2013), and in some cases this is associated
with somatic mutations leading to premature termination
codons (Cimino et al., 2014).
The absence of MCCs in sTAg-expressing mice may also be
related to the fact that our modeling strategy does not target
transgene expression to a cell population competent to give
rise to MCC. The potential cell of origin of MCC is con-
troversial and may include epidermal cells, Merkel
cell progenitors residing in the epidermis, or even differen-
tiated Merkel cells. Expression of the epithelial marker
p63 in MCC (Asioli et al., 2007; Hall et al., 2012; Stetsenko
et al., 2013) is in keeping with the idea that at least
some MCCs are derived from epidermal basal cells or
Merkel cell progenitors, which co-express epidermal and
Merkel cell markers. Additional modeling studies, testing the
tumorigenic potential of sTAg alone or combined with tLTAg,
will be required to assess whether expression of MCPyV TAgs
in appropriate progenitor cells is sufficient to drive MCC
development in mice.
In summary, we have utilized a powerful transgenic mouse
embryo screening assay, coupled with Cre-inducible mouse
lines for postnatal transgene induction, to establish that
MCPyV sTAg has robust transforming activity in vivo. Our
data suggest that sTAg functions as an oncogenic driver in
MCC and perhaps other MCPyV-associated human tumors
and may provide an important target for drug development.
Future studies will focus on identifying the mechanism by
which sTAg drives transformed phenotypes in vivo, and
ascertaining whether combined expression of MCPyV sTAg
and tLTAg in defined cell populations in the skin can give rise
to murine tumors resembling human MCCs.
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Figure 4. Lack of epithelial transformation by an LSD sTAg mutant. (a) Transgene construction identical to K5-sTAg in Figure 1a, except for 91–95A substitutions,
which block sTAg binding to Fbxw7. (b) Similar histology of acral skin and tongue in sections from control and K5-sTAg91-95A transgenic mice, despite robust RFP
expression in basal layer cells of transgenic mice. (c) Similar profile of epidermal markers and proliferation and lack of CC3 and gH2AX immunostaining in control
and K5-sTAg91–95A transgenic acral skin. Scale bars¼ 50mm. H&E, hematoxylin and eosin; K5, keratin 5; LTAg, large T antigen; RFP, red fluorescent protein;
sTAg, small T antigen.
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MATERIALS AND METHODS
Generation of transgenic mice
The K5-sTAg-IRES-tdTomato (K5-sTAg) transgenic cassette was gen-
erated as follows: a sTAg cDNA sequence (GenBank EU375803; nts
196–756) including an additional upstream Kozak sequence, a 50
NotI site, and a 30 SnaBI site was synthesized de novo by GenScript
USA (Piscataway, NJ) and cloned into the pUC57 vector. A NotI-
sTAg-SnaBI digested fragment was then subcloned into the pBK5
vector (Ramirez et al., 1994) containing an IRES-tdTomato sequence
synthesized and subcloned by GenScript USA based on the pLVX-
IRES-tdTomato vector (Clontech, cat# 631238; nts 2842–4847). Site
directed mutagenesis using the GENEART Site-Directed Mutagenesis
System (Life Technologies, Grand Island, NY) was used to create a
leucine to alanine substitution at amino acid 142 to generate the K5-
sTAgL142A cassette. The K5-sTAg91–95A cassette was generated
with a nucleotide sequence substituting amino acid residues 91–95
with alanines (Kwun et al., 2013) by GenScript USA using site
directed mutagenesis. Following sequence verification, BssHII-
digested fragments of each of the above constructs were purified
and injected into (C57BL/6 X SJL) F2 mouse eggs in the University of
Michigan Transgenic Core. The inducible K5-loxP-eGFP-loxP-sTAg
(KLEsT) transgenic cassette was subcloned by GenScript USA using
the pUC57-sTAg vector described above into a SnaBI-blunt restriction
digested K5-loxP-eGFP-loxP (Allen et al., 2003) vector backbone.
Analysis of preterm embryos
To avoid loss of transgenic founders with lethal phenotypes, preterm
embryos from all conventional K5 driven transgenic mice were
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harvested at e18.5 and founders identified by PCR using transgene-
specific primers as described in Supplementary Material online. The
number of transgene-positive/total potential embryonic founders was
as follows: K5-sTAg: 11/92, K5-sTAgL142A: 5/18, and K5-sTAg91-
95A: 11/122. Detailed analysis of sTAg embryo harvests is provided
in Supplementary Table S1 online.
Postnatal transgene induction
KLEsT mice were crossed with K5-CreERT2 (Indra et al., 1999) mice
(kindly provided by Drs Pierre Chambon and Daniel Metzger) to
generate K5-CreERT2;KLEsT (iK5;KLEsT) bitransgenic mice for
analysis. Recombination leading to sTAg expression was induced in
P21 mice by five daily oral gavage administrations of 75 mg kg 1
tamoxifen (Sigma-Aldrich, St. Louis, MO) resuspended in corn oil.
KLEsT founder mice were crossed with C57BL/6J breeders (Jackson
Laboratory, Bar Harbor, ME) to establish transgenic lines. All mice
were housed and maintained according to University of Michigan
institutional guidelines. Procedures involving animal experimentation
were approved by the University Committee on the Use and Care of
Animals, animal protocol #PRO00004440.
Tissue collection and immunostaining
All tissues were fixed overnight at room temperature in 10% neutral
buffered formalin, transferred to 70% EtOH, processed, and paraffin
embedded. For immunohistochemical staining, tissue was sectioned
at 5mm, deparaffinized, and rehydrated prior to antigen retrieval in
boiling citrate-based buffer (0.01 mol l 1 citric acid, pH 6.8). Endo-
genous peroxidases were quenched with 3% H2O2, followed by
blocking in 5% goat serum and incubation with primary antibodies
(see Supplementary Material online for details). Bound antibodies
were detected with the Vector M.O.M. peroxidase or fluorescein
Immunodetection Kits (Vector Laboratories, Burlington, CA), using
SigmaFast diaminobenzidene as a peroxidase substrate or Alexa-
Fluor594 (Jackson ImmunoResearch, West Grove, PA) for immuno-
fluorescence. Nuclei were counterstained with hematoxylin followed
by Permount (Fisher Scientific, Fair Lawn, NJ) mounting or immuno-
fluorescence visualized with ProLong Gold Antifade Reagent with
DAPI (Life Technologies, Grand Island, NY).
Immunoblotting and immunoprecipitation
Epidermal lysates were prepared by mechanical homogenization in
RIPA buffer supplemented with HALT phosphatase inhibitor cocktail
(Thermo Scientific, Rockford, IL) and Complete mini protease inhi-
bitor cocktail (Roche, Manheim, Germany) followed by protein
quantification using standard Bradford method with Bio-Rad Protein
Assay dye reagent (Bio-Rad Laboratories, Hercules, CA). For immu-
noprecipitation, 500mg of pre-cleared protein lysate was incubated
with 5mg of primary mouse 2t2 antibody overnight at 4 1C followed
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by binding to Protein G Sepharose beads (GE Healthcare, Sweden).
Beads were centrifuged, washed, and the pellet dissolved in Laemmli
buffer. Supernatants were separated on 4–20% or 12% gradient SDS-
polyacrylamide gels followed by transfer to Immobilon-P membranes
(Millipore, Billerica, MA). Antibody details are listed in Supple-
mentary Material online. Detection was carried out with SuperSignal
West Pico or Femto chemiluminescent substrates (Thermo Scientific).
Quantification of epidermal thickness
Epidermal thickness at each site (tail, ear, volar, and snout) was
measured as an average from four fields in three independent mice.
Statistics were performed using an unpaired two-tailed Student’s t test.
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